Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
December 22, 2025
Labor & Employment Law Perspectives
‘Tis the Season
‘Tis the Season… You probably do not think of HR compliance when you hear the phrase. But the end of 2025 is a good time — even in the…
January 27, 2026
Events
Fashion Law 2025 Year in Review
In 2025, the fashion industry faced significant challenges and opportunities driven by geopolitical shifts, rising tariffs and trade policy changes, and evolving consumer expectations, while innovation in brand protection and strategic partnerships supported resilience and growth.
December 22, 2025
Foley Viewpoints
Guyana: A Primer on a Strategic U.S. Caribbean & South American Ally
Guyana does not currently have a binding corporate governance code, and minority shareholder protections are relatively weak. Foreign investors must therefore structure joint ventures and other partnerships carefully, using shareholder agreements, board representation rights, and dispute resolution clauses to safeguard their interests.